Journal
Lung Cancer
Publication Date
4-1-2022
Volume
166
First Page
270
Last Page
278
Document Type
Open Access Publication
DOI
10.1016/j.lungcan.2021.10.007
Rights and Permissions
Bauml JM, Li BT, Velcheti V, Govindan R, Curioni-Fontecedro A, Dooms C, Takahashi T, Duda AW, Odegaard JI, Cruz-Guilloty F, Jin L, Zhang Y, Anderson A, Skoulidis F. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Lung Cancer. 2022 Apr;166:270-278. doi: 10.1016/j.lungcan.2021.10.007. © 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).
Recommended Citation
Bauml, Joshua M; Li, Bob T; Velcheti, Vamsidhar; Govindan, Ramaswamy; Curioni-Fontecedro, Alessandra; Dooms, Christophe; Takahashi, Toshiaki; Duda, Andrew W; Odegaard, Justin I; Cruz-Guilloty, Fernando; Jin, Liming; Zhang, Ying; Anderson, Abraham; and Skoulidis, Ferdinandos, "Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib." Lung Cancer. 166, 270 - 278. (2022).
https://digitalcommons.wustl.edu/oa_4/1420
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
